Comparison · NCT02057640-deaths
DL1 - 3mg Lxazomib vs DL2 - 4mg Lxazomib: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DL1 - 3mg Lxazomib vs DL2 - 4mg Lxazomib: deaths from any cause. Trial comparisons, record NCT02057640-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02057640-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.51 | 1 | wilson | |
| Risk in group 2 | 0.75 | 0.468 | 0.911 | wilson | |
| Risk difference, group 1 minus group 2 | 0.25 | -0.266 | 0.532 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.962 | 1.85 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more death from any cause on DL1 - 3mg Lxazomib than on DL2 - 4mg Lxazomib | 4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DL1 - 3mg Lxazomib | Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28 | 4 | 4 | EG000 |
| Group 2 | DL2 - 4mg Lxazomib | Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28 | 9 | 12 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 30 days post last study drug administration
Source ClinicalTrials.gov
Trial
- Title
- MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
- NCT number
- NCT02057640
- Phases
- PHASE1, PHASE2
- Conditions
- Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
- Interventions
- Panobinostat, Dexamethasone, MLN9708
- Lead sponsor
- Jason Valent
- Results first posted
- 2019-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02057640?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02057640-deaths